|
Allergan plc
Ticker Symbol: AGN* CUSIP: G0177J108 Previous CUSIP: 00507K103 Exchange: NYSE
* NOTE: This security is no longer trading as of 5/11/2020
Company's Online Profile
BUSINESS: Allergan plc is a unique, global pharmaceutical company and a leader in a new industry model, Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world. Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
|
Notes: May 08, 2020 -- Allergan plc (NYSE: AGN) (“Allergan”) announced that AbbVie has now completed the acquisition of Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the “Scheme”), which became effective earlier today, May 8, 2020. _______________ June 15, 2015 -- Actavis plc announced that the company has adopted Allergan plc (NYSE: AGN) as its new global name and will begin trading today under a new symbol AGN after ringing The Opening Bell at the New York Stock Exchange. The company name change follows the acquisition of Allergan in March 2015 and the approval of the name change by Actavis shareholders on June 5.__________________ Feb. 19, 2015 -- Actavis plc (NYSE: ACT) today announced that it is commencing concurrent offerings totaling $8.4 billion, comprising $4.2 billion of Ordinary Shares and $4.2 billion of Mandatory Convertible Preferred Shares, Series A, each in a separate registered public offering, subject to market and other conditions.________________ Feb. 18, 2015 -- Actavis plc (NYSE: ACT) today announced that it will adopt a new corporate name Allergan following the anticipated successful completion of the acquisition of Allergan, Inc. The Company said that it intends to use the Allergan name as its corporate name and for its global branded pharmaceutical portfolio, and will retain the Actavis name for select geographic regions and product portfolios. The change in corporate name would be subject to approval by Actavis' shareholders at its Annual General Meeting later this year.
|
Previous Ticker Symbol: ACT Changed: 6/15/2015
Previous Name: Actavis plc Changed: 6/15/2015
Large Cap Stock -
Market Value $54.6 Billion
|
Company's Online Information Links
|
| Company's Online SEC EDGAR Filings |
| Company's Email Address Links |
| Foreign Address and Phone Numbers |
| Address: Euro House, Euro Business Park, Little Island Business Park, Cork, Ireland |
| Main Phone Number |
+353 214619040 |
| Address and Phone Numbers |
| U.S. Representative |
N.A. |
| Address: Morris Corporate Center III, 400 Interpace Parkway, Parsippany, NJ 07054 |
| Main Phone Number |
862-261-7000 |
| Fax Number |
Not Available |
| Investor Relations
Lisa DeFrancesco
|
862-261-7152
|
| Toll Free Phone Number |
800-272-5525 |
| CEO - Brent L. Saunders |
CFO - Matthew M. Walsh |
Find a problem? Please use our Feedback Page or Email us.
Have you filled out our Guestbook? If not, please do.
|
|
